BACKGROUND: In vertebrates, DNA methylation occurs primarily at CG dinucleotides but recently, non-CG methylation has been found at appreciable levels in embryonic stem cells. MATERIALS & METHODS: To assess non-CG methylation in cancer, we compared the extent of non-CG methylation at several biologically important CG islands in prostate cancer and normal cell lines. An assessment of the promoter CG islands EVX1 and FILIP1L demonstrates a fourfold higher rate of non-CG methylation at EVX1 compared with FILIP1L across all cell lines. These loci are densely methylated at CG sites in cancer. RESULTS: No significant difference in non-CG methylation was demonstrated between cancer and normal. Treatment of cancer cell lines with 5-azacytidine significantly reduced methylation within EVX1 at CG and CC sites, preferentially. CONCLUSION: Non-CG methylation does not correlate with CG methylation at hypermethylated promoter regions in cancer. Furthermore, global inhibition of DNA methyltransferases does not affect all methylated cytosines uniformly.
BACKGROUND: In vertebrates, DNA methylation occurs primarily at CG dinucleotides but recently, non-CG methylation has been found at appreciable levels in embryonic stem cells. MATERIALS & METHODS: To assess non-CG methylation in cancer, we compared the extent of non-CG methylation at several biologically important CG islands in prostate cancer and normal cell lines. An assessment of the promoter CG islands EVX1 and FILIP1L demonstrates a fourfold higher rate of non-CG methylation at EVX1 compared with FILIP1L across all cell lines. These loci are densely methylated at CG sites in cancer. RESULTS: No significant difference in non-CG methylation was demonstrated between cancer and normal. Treatment of cancer cell lines with 5-azacytidine significantly reduced methylation within EVX1 at CG and CC sites, preferentially. CONCLUSION: Non-CG methylation does not correlate with CG methylation at hypermethylated promoter regions in cancer. Furthermore, global inhibition of DNA methyltransferases does not affect all methylated cytosines uniformly.
Authors: Christoph Bock; Sabine Reither; Thomas Mikeska; Martina Paulsen; Jörn Walter; Thomas Lengauer Journal: Bioinformatics Date: 2005-09-01 Impact factor: 6.937
Authors: B H Ramsahoye; D Biniszkiewicz; F Lyko; V Clark; A P Bird; R Jaenisch Journal: Proc Natl Acad Sci U S A Date: 2000-05-09 Impact factor: 11.205
Authors: C S Malone; M D Miner; J R Doerr; J P Jackson; S E Jacobsen; R Wall; M Teitell Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: Gerwin Heller; Thomas Brodowicz; Angelika M Starzer; Anna S Berghoff; Rainer Hamacher; Erwin Tomasich; Katharina Feldmann; Teresa Hatziioannou; Stefan Traint; Wolfgang Lamm; Iris M Noebauer-Huhmann; Julia Furtner; Leonhard Müllauer; Gabriele Amann; Sebastian Bauer; Hans-Ulrich Schildhaus; Matthias Preusser Journal: J Immunother Cancer Date: 2021-03 Impact factor: 13.751
Authors: Qiang Liu; Gang Liu; Darryl T Martin; Yu-Tong Xing; Robert M Weiss; Jun Qi; Jian Kang Journal: Asian J Androl Date: 2021 Sep-Oct Impact factor: 3.285
Authors: Anna Sophie Berghoff; Thorsten Fuereder; Angelika Martina Starzer; Gerwin Heller; Erwin Tomasich; Thomas Melchardt; Katharina Feldmann; Teresa Hatziioannou; Stefan Traint; Christoph Minichsdorfer; Ursula Schwarz-Nemec; Maja Nackenhorst; Leonhard Müllauer; Matthias Preusser Journal: J Immunother Cancer Date: 2022-03 Impact factor: 12.469